{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:29Z","timestamp":1791478049143,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Viatris"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40265-025-02234-5","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:51:10Z","timestamp":1757083870000},"page":"1289-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Current Evidence on Celecoxib Safety in the Management of Chronic Musculoskeletal Conditions: An Umbrella Review"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-5303","authenticated-orcid":false,"given":"Charlotte","family":"Beaudart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brabant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alokail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"issue":"10258","key":"2234_CR1","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"Suppl 2","key":"2234_CR2","doi-asserted-by":"crossref","first-page":"S243","DOI":"10.1093\/geront\/gnw002","volume":"56","author":"AM Briggs","year":"2016","unstructured":"Briggs AM, et al. Musculoskeletal health conditions represent a global threat to healthy aging: a report for the 2015 World Health Organization world report on ageing and health. Gerontologist. 2016;56(Suppl 2):S243\u201355.","journal-title":"Gerontologist"},{"issue":"1","key":"2234_CR3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40520-024-02883-8","volume":"36","author":"N Veronese","year":"2024","unstructured":"Veronese N, et al. Mediterranean diet and osteoarthritis: an update. Aging Clin Exp Res. 2024;36(1):231.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2234_CR4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s40520-025-03015-6","volume":"37","author":"X Lan","year":"2025","unstructured":"Lan X, et al. Physical modalities for the treatment of knee osteoarthritis: a network meta-analysis. Aging Clin Exp Res. 2025;37(1):121.","journal-title":"Aging Clin Exp Res"},{"issue":"18","key":"2234_CR5","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s40265-020-01423-8","volume":"80","author":"C Beaudart","year":"2020","unstructured":"Beaudart C, et al. Symptomatic efficacy of pharmacological treatments for knee osteoarthritis: a systematic review and a network meta-analysis with a 6-month time horizon. Drugs. 2020;80(18):1947\u201359.","journal-title":"Drugs"},{"issue":"1","key":"2234_CR6","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5114\/aoms.2018.73714","volume":"15","author":"K Ma","year":"2019","unstructured":"Ma K, et al. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. Arch Med Sci. 2019;15(1):33\u201354.","journal-title":"Arch Med Sci"},{"issue":"1","key":"2234_CR7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41598-023-49761-3","volume":"14","author":"A Shetty","year":"2024","unstructured":"Shetty A, et al. A systematic review and network meta-analysis of pharmaceutical interventions used to manage chronic pain. Sci Rep. 2024;14(1):1621.","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"2234_CR8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40266-019-00660-1","volume":"36","author":"C Cooper","year":"2019","unstructured":"Cooper C, et al. Safety of oral non-selective non-steroidal anti-inflammatory drugs in osteoarthritis: what does the literature say? Drugs Aging. 2019;36(Suppl 1):15\u201324.","journal-title":"Drugs Aging"},{"issue":"5","key":"2234_CR9","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/2040622317749394","volume":"9","author":"ILP Beales","year":"2018","unstructured":"Beales ILP. Time to reappraise the therapeutic place of celecoxib. Ther Adv Chronic Dis. 2018;9(5):107\u201310.","journal-title":"Ther Adv Chronic Dis"},{"issue":"7","key":"2234_CR10","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339(7): b2535.","journal-title":"BMJ"},{"issue":"3","key":"2234_CR11","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/XEB.0000000000000055","volume":"13","author":"E Aromataris","year":"2015","unstructured":"Aromataris E, et al. Summarizing systematic reviews: methodological development, conduct and reporting of an umbrella review approach. Int J Evid Based Healthc. 2015;13(3):132\u201340.","journal-title":"Int J Evid Based Healthc"},{"issue":"2","key":"2234_CR12","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1017\/S0266462312000086","volume":"28","author":"A Morrison","year":"2012","unstructured":"Morrison A, et al. The effect of English-language restriction on systematic review-based meta-analyses: a systematic review of empirical studies. Int J Technol Assess Health Care. 2012;28(2):138\u201344.","journal-title":"Int J Technol Assess Health Care"},{"key":"2234_CR13","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jclinepi.2021.04.012","volume":"137","author":"AI Dobrescu","year":"2021","unstructured":"Dobrescu AI, et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review. J Clin Epidemiol. 2021;137:209\u201317.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"2234_CR14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2522\/ptj.20070043","volume":"88","author":"G Jamtvedt","year":"2008","unstructured":"Jamtvedt G, et al. Physical therapy interventions for patients with osteoarthritis of the knee: an overview of systematic reviews. Phys Ther. 2008;88(1):123\u201336.","journal-title":"Phys Ther"},{"issue":"7\u20138","key":"2234_CR15","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1345\/aph.10382","volume":"35","author":"DM Ashcroft","year":"2001","unstructured":"Ashcroft DM, et al. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother. 2001;35(7\u20138):829\u201334.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"2234_CR16","volume":"16","author":"BR Cheng","year":"2021","unstructured":"Cheng BR, et al. Cardiovascular safety of celecoxib in rheumatoid arthritis and osteoarthritis patients: a systematic review and meta-analysis. PLoS ONE. 2021;16(12): e0261239.","journal-title":"PLoS ONE"},{"key":"2234_CR17","first-page":"3831","volume":"4","author":"S Garner","year":"2002","unstructured":"Garner S, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2002;4:3831.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"2234_CR18","first-page":"2095","volume":"6","author":"M Fidahic","year":"2017","unstructured":"Fidahic M, et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017;6(6):2095.","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"2234_CR19","first-page":"9865","volume":"5","author":"L Puljak","year":"2017","unstructured":"Puljak L, et al. Celecoxib for osteoarthritis. Cochrane Database Syst Rev. 2017;5(5):9865.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2234_CR20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-012-0717-6","volume":"48","author":"S Jarupongprapa","year":"2013","unstructured":"Jarupongprapa S, Ussavasodhi P, Katchamart W. Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non-selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systematic review and meta-analysis. J Gastroenterol. 2013;48(7):830\u20138.","journal-title":"J Gastroenterol"},{"issue":"10","key":"2234_CR21","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1097\/MEG.0b013e328349de81","volume":"23","author":"X Wang","year":"2011","unstructured":"Wang X, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23(10):876\u201380.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"3","key":"2234_CR22","doi-asserted-by":"crossref","first-page":"R644","DOI":"10.1186\/ar1704","volume":"7","author":"RA Moore","year":"2005","unstructured":"Moore RA, et al. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis Res Ther. 2005;7(3):R644\u201365.","journal-title":"Arthritis Res Ther"},{"issue":"13","key":"2234_CR23","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1001\/jama.296.13.jrv60015","volume":"296","author":"J Zhang","year":"2006","unstructured":"Zhang J, Ding EL, Song Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials. JAMA. 2006;296(13):1619\u201332.","journal-title":"JAMA"},{"key":"2234_CR24","doi-asserted-by":"crossref","first-page":"16827","DOI":"10.1038\/srep16827","volume":"5","author":"C Zeng","year":"2015","unstructured":"Zeng C, et al. Effectiveness and safety of glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015;5:16827.","journal-title":"Sci Rep"},{"issue":"7","key":"2234_CR25","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.cgh.2007.03.011","volume":"5","author":"A Rostom","year":"2007","unstructured":"Rostom A, et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol. 2007;5(7):818\u201328.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2234_CR26","first-page":"3031","volume":"19","author":"M Fan","year":"2020","unstructured":"Fan M, et al. Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med. 2020;19(4):3031\u201341.","journal-title":"Exp Ther Med"},{"issue":"7","key":"2234_CR27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1185\/03007995.2011.581274","volume":"27","author":"SR Mallen","year":"2011","unstructured":"Mallen SR, Essex MN, Zhang R. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Curr Med Res Opin. 2011;27(7):1359\u201366.","journal-title":"Curr Med Res Opin"},{"issue":"6","key":"2234_CR28","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1136\/annrheumdis-2015-207677","volume":"75","author":"R Wang","year":"2016","unstructured":"Wang R, Dasgupta A, Ward MM. Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. 2016;75(6):1152\u201360.","journal-title":"Ann Rheum Dis"},{"issue":"20","key":"2234_CR29","volume":"95","author":"C Xu","year":"2016","unstructured":"Xu C, et al. Efficacy and safety of celecoxib therapy in osteoarthritis: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(20): e3585.","journal-title":"Medicine (Baltimore)"},{"issue":"7365","key":"2234_CR30","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.325.7365.619","volume":"325","author":"JJ Deeks","year":"2002","unstructured":"Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619.","journal-title":"BMJ"},{"issue":"10","key":"2234_CR31","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jama.284.10.1247","volume":"284","author":"FE Silverstein","year":"2000","unstructured":"Silverstein FE, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247\u201355.","journal-title":"JAMA"},{"issue":"4","key":"2234_CR32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s40265-025-02162-4","volume":"85","author":"G Honvo","year":"2025","unstructured":"Honvo G, et al. Safety of anti-osteoarthritis medications: a systematic literature review of post-marketing surveillance studies. Drugs. 2025;85(4):505\u201355.","journal-title":"Drugs"},{"issue":"3","key":"2234_CR33","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","volume":"49","author":"O Bruyere","year":"2019","unstructured":"Bruyere O, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337\u201350.","journal-title":"Semin Arthritis Rheum"},{"issue":"11","key":"2234_CR34","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1016\/j.joca.2019.06.011","volume":"27","author":"RR Bannuru","year":"2019","unstructured":"Bannuru RR, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578\u201389.","journal-title":"Osteoarthritis Cartilage"},{"issue":"1","key":"2234_CR35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40520-024-02714-w","volume":"36","author":"G Herrero-Beaumont","year":"2024","unstructured":"Herrero-Beaumont G, et al. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clin Exp Res. 2024;36(1):45.","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"2234_CR36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1053\/bega.2001.0236","volume":"15","author":"CJ Hawkey","year":"2001","unstructured":"Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol. 2001;15(5):801\u201320.","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"17","key":"2234_CR37","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1056\/NEJMp048286","volume":"351","author":"EJ Topol","year":"2004","unstructured":"Topol EJ. Failing the public health \u2013 rofecoxib, Merck, and the FDA. N Engl J Med. 2004;351(17):1707\u20139.","journal-title":"N Engl J Med"},{"issue":"13","key":"2234_CR38","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1001\/jama.296.13.jrv60011","volume":"296","author":"P McGettigan","year":"2006","unstructured":"McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA. 2006;296(13):1633\u201344.","journal-title":"JAMA"},{"issue":"26","key":"2234_CR39","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, et al. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"12","key":"2234_CR40","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjmed.2017.06.028","volume":"130","author":"DH Solomon","year":"2017","unstructured":"Solomon DH, et al. The risk of major NSAID toxicity with celecoxib, ibuprofen, or naproxen: a secondary analysis of the PRECISION trial. Am J Med. 2017;130(12):1415\u201322.","journal-title":"Am J Med"},{"issue":"11","key":"2234_CR41","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/apt.14610","volume":"47","author":"ND Yeomans","year":"2018","unstructured":"Yeomans ND, et al. Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. Aliment Pharmacol Ther. 2018;47(11):1453\u201363.","journal-title":"Aliment Pharmacol Ther"},{"issue":"44","key":"2234_CR42","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1093\/eurheartj\/ehx508","volume":"38","author":"F Ruschitzka","year":"2017","unstructured":"Ruschitzka F, et al. Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (prospective randomized evaluation of celecoxib integrated safety versus ibuprofen or naproxen ambulatory blood pressure measurement) trial. Eur Heart J. 2017;38(44):3282\u201392.","journal-title":"Eur Heart J"},{"issue":"6","key":"2234_CR43","first-page":"611","volume":"8","author":"S Obeid","year":"2022","unstructured":"Obeid S, et al. Cardiorenal risk of celecoxib compared with naproxen or ibuprofen in arthritis patients: insights from the PRECISION trial. Eur Heart J. 2022;8(6):611\u201321.","journal-title":"Eur Heart J"},{"issue":"9","key":"2234_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001098","volume":"8","author":"P McGettigan","year":"2011","unstructured":"McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9): e1001098.","journal-title":"PLoS Med"},{"issue":"7S1","key":"2234_CR45","doi-asserted-by":"crossref","first-page":"S184","DOI":"10.1016\/j.arth.2025.03.015","volume":"40","author":"SS Antonioli","year":"2025","unstructured":"Antonioli SS, et al. Rates of postoperative heart failure among type 2 diabetics with use of nonsteroidal anti-inflammatory drugs for total knee arthroplasty. J Arthroplasty. 2025;40(7S1):S184\u20137.","journal-title":"J Arthroplasty"},{"issue":"3","key":"2234_CR46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1080\/03009742.2025.2467556","volume":"54","author":"A Kim","year":"2025","unstructured":"Kim A, et al. Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study. Scand J Rheumatol. 2025;54(3):204\u201312.","journal-title":"Scand J Rheumatol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02234-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02234-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T14:19:45Z","timestamp":1759241985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02234-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["2234"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02234-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was supported by Viatris. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. J-YR\u2019s participation in this work was supported by the Distinguished Scientist Fellowship Program (DSFP) of the King Saud University, Riyadh, Kingdom of Saudi Arabia.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CBe has received personal speaker fees from Nutricia outside the submitted work. J-YR has received consulting and speakers\u2019 fees from Viatris. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Orifarm, Sanofi, UCB, and Viatris outside the submitted work. CBr has no conflicts of interest that might be relevant to the contents of this manuscript. The authors alone are responsible for the views expressed in this article and they do not necessarily represent the views, decisions or policies of the institutions with which they are affiliated.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation and publication)"}},{"value":"OB, CBe, and J-YR initiated the research question. OB, CBe, and J-YR were the main investigators. CB and OB drafted the protocol. CBe ran the search strategies and identified potential references to be included in the project. OB, CBe, and CBr screened and selected relevant references. CBr extracted the data, and OB and CBe double checked the data extraction. OB, CBe, and CBr performed the risk-of-bias assessment. The results were interpreted by all authors. OB and CBe wrote the first draft of the manuscript. All authors reviewed and approved the final manuscript.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All materials related to this work are freely available on the Open Science Framework deposit (\n                      \n                      ).","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}